Related Experiment Video
Updated: Jun 15, 2026
Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
[Suppression of experimental inflammation by anti-fungal agent liranaftate in mice]
Naho Maruyama1, Yoshie Abe, Tatsuya Hisajima
1Teikyo University Institute of Medical Mycology.
Abstract:
To evaluate the anti-inflammatory activity of the thiocarbamate antifungal agent liranaftate, the edema and the neutrophil accumulation detected by the activity of neutrophil marker enzyme, myeloperoxidase (MPO), were examined following application of liranaftate to mouse ears with inflammation induced by phorbol 12-myristate 13-acetate (PMA). Topical 20 microl administration of liranaftate in a dose-range between 1-4% suppressed the increase in ear thickness 6 hr after PMA application dose-dependently. Similarly, it decreased the weight increase of an ear section after 24 hr dose-dependently. More than 1% of liranaftate also suppressed augmentation of MPO activity of the ear section. This and histological observation indicate that liranaftate treatment suppressed neutrophil accumulation in PMA-applied ear lesion. From these results, we discussed that liranaftate might suppress inflammatory symptoms caused by trychophytosis in a clinical condition.
Insights
Liranaftate, an antifungal medication, effectively reduced inflammation and neutrophil accumulation in mouse models. This suggests potential therapeutic benefits for inflammatory skin conditions like trychophytosis.
Area of Science:
- Pharmacology
- Dermatology
- Inflammation Research
Context:
- Phorbol 12-myristate 13-acetate (PMA) is a common inducer of skin inflammation in research models.
- Neutrophil accumulation, indicated by myeloperoxidase (MPO) activity, is a key feature of inflammatory responses.
- Liranaftate is a thiocarbamate antifungal agent with potential anti-inflammatory properties.
Purpose:
- To investigate the anti-inflammatory effects of liranaftate.
- To assess liranaftate's impact on edema and neutrophil infiltration in a mouse ear inflammation model.
Summary:
- Topical liranaftate (1-4%) dose-dependently suppressed PMA-induced ear swelling and weight increase.
- Liranaftate significantly reduced myeloperoxidase (MPO) activity, indicating decreased neutrophil accumulation.
- Histological analysis confirmed reduced neutrophil infiltration in liranaftate-treated lesions.
Impact:
- Liranaftate demonstrates significant anti-inflammatory activity in a preclinical model.
- These findings suggest liranaftate may be a viable therapeutic option for managing inflammatory symptoms associated with fungal infections like trychophytosis.
